- Mediterranean Fever (also known as Familial Mediterranean Fever or FMF), a genetic inflammatory disorder, requires ongoing management through various treatment options to alleviate symptoms and prevent complications
- The escalating demand for Mediterranean fever treatment is primarily fueled by the increasing diagnosis rates, rising patient awareness, and a growing preference for effective long-term management solutions
- North America dominates Mediterranean fever treatment market with the largest revenue share of 40.01% in 2025, characterized by early adoption of advanced therapies, high healthcare expenditure, and a strong presence of key industry players. The U.S. is experiencing substantial growth in Mediterranean fever treatment, particularly in specialized clinics and research institutions, driven by innovations from both established pharmaceutical companies and startups focusing on targeted therapies and personalized medicine
- Asia-Pacific is expected to be the fastest-growing region in Mediterranean fever treatment market during the forecast period due to increasing healthcare infrastructure and rising disposable incomes
- The colchicine segment is expected to dominate Mediterranean fever treatment market with a market share of 43.2% in 2025, driven by its established efficacy as a first-line treatment and ease of administration
